Fidelity® Select Pharmaceuticals Port (FPHAX)

23.87 -0.14  -0.58% Jul 10 USD
View Full Chart
Total Returns Chart

Key Stats

Net Asset Value 23.87
Turnover Ratio 52.00%
1 Year Fund Level Flows 25.01M

Performance & Returns

  Total Return Cat. Total Return (NAV) % Rank in Cat. (NAV)
1M 1.40% 1.84% 49
3M 12.12% 17.08% 59
6M 4.33% 5.67% 48
YTD 5.49% 6.45% 47
1Y 22.73% 17.72% 26
3Y 13.48% 11.42% 32
5Y 4.41% 6.33% 67
10Y 14.62% 15.85% 71
15Y 11.83% 11.03% 38
20Y -- 8.76% --
As of July 10, 2020. Returns for periods of 1 year and above are annualized.

Asset Allocation

Type % Net % Long % Short
Cash 3.25% 3.25% 0.00%
Stock 96.46% 96.46% 0.00%
Bond 0.00% 0.00% 0.00%
Convertible 0.00% 0.00% 0.00%
Preferred 0.00% 0.00% 0.00%
Other 0.29% 0.29% 0.00%
As of May 31, 2020

Region Exposure

Americas 55.37%
North America 55.37%
Latin America 0.00%
Greater Europe 41.08%
United Kingdom 15.48%
Europe Developed 25.21%
Europe Emerging 0.39%
Africa/Middle East 0.00%
Greater Asia 3.55%
Japan 1.49%
Australasia 0.00%
Asia Developed 0.00%
Asia Emerging 2.06%
Market Classification
% Developed Markets 97.55%
% Emerging Markets 2.45%
As of May 31, 2020. Region breakdown data is calculated by using the long position holdings of the portfolio.

Stock Sector Exposure

Basic Materials 0.00%
Communication Services 0.00%
Consumer Cyclical 0.00%
Consumer Defensive 0.00%
Energy 0.00%
Financial Services 0.00%
Healthcare 100.0%
Industrials 0.00%
Real Estate 0.00%
Technology 0.00%
Utilities 0.00%
As of May 31, 2020

Stock Market Capitalization

Giant 68.99%
Large 8.84%
Medium 17.01%
Small 4.93%
Micro 0.23%
As of May 31, 2020

Stock Style Exposure

Large Cap Value 30.18%
Large Cap Blend 42.97%
Large Cap Growth 6.11%
Mid Cap Value 3.27%
Mid Cap Blend 1.97%
Mid Cap Growth 11.19%
Small Cap Value 0.00%
Small Cap Blend 1.56%
Small Cap Growth 2.74%
As of May 31, 2020
View More Holdings

Top 10 Holdings

Symbol Name % Weight Price % Chg
AZN AstraZeneca PLC ADR 11.92% 53.28 -0.89%
SNY Sanofi SA ADR 9.09% 50.96 +1.35%
JNJ Johnson & Johnson 7.74% 145.10 +1.92%
BMY Bristol-Myers Squibb Company 7.12% 57.77 +0.59%
ROG Roche Holding AG Dividend Right Cert. 6.71% -- --
LLY Eli Lilly and Co 5.90% 162.09 -0.78%
MRK Merck & Co Inc 4.79% 77.40 +0.87%
NVS Novartis AG ADR 4.45% 86.00 -1.16%
ZTS Zoetis Inc Class A 3.79% 138.50 +1.02%
AMGN Amgen Inc 3.73% 250.04 +0.40%
As of May 31, 2020
Advertisement

Basic Info

Investment Strategy
The investment seeks capital appreciation. The fund normally invests at least 80% of assets in companies engaged in the research, development, manufacture, sale, or distribution of pharmaceuticals and drugs of all types. It invests in domestic and foreign issuers. The fund invests primarily in common stocks. It uses fundamental analysis of factors such as each issuer's financial condition and industry position, as well as market and economic conditions to select investments. The fund is non-diversified.
General
Security Type Mutual Fund
Oldest Share Symbol FPHAX
Equity Style Large Cap/Blend
Fixed Income Style --
Broad Asset Class Sector Equity
Broad Category Equity
Category Name Health
Prospectus Objective Specialty - Health
Fund Owner Firm Name Fidelity Investments
Benchmark Index
S&P 500 TR USD 100.0%
Reports
One Page Report Download

Manager Info

Name Tenure
Karim Suwwan de Felipe 3.00 yrs

Net Fund Flows

1M -16.34M
3M 60.90M
6M 29.33M
YTD 29.33M
1Y 25.01M
3Y -322.42M
5Y -1.295B
10Y -419.77M
As of June 30, 2020

Risk Info

Beta (5Y) 0.7797
Historical Sharpe Ratio (10Y) 1.012
Historical Sortino (All) 0.7551
Daily Value at Risk (VaR) 1% (All) 3.00%
Monthly Value at Risk (VaR) 1% (All) 12.31%

Fundamentals

Dividend Yield TTM (7-10-20) 1.25%
30-Day SEC Yield --
7-Day SEC Yield --
Weighted Average PE Ratio 28.36
Weighted Average Price to Sales Ratio 4.449
Weighted Average Price to Book Ratio 4.917
Weighted Median ROE 19.56%
Weighted Median ROA 1.14%
Forecasted Dividend Yield 2.18%
Forecasted PE Ratio 16.68
Forecasted Price to Sales Ratio 4.200
Forecasted Price to Book Ratio 4.949
Number of Holdings 62
As of May 31, 2020

Growth Estimates

Forecasted 5 Yr Earnings Growth 8.87%
Forecasted Book Value Growth -2.83%
Forecasted Cash Flow Growth 7.83%
Forecasted Earnings Growth 7.77%
Forecasted Revenue Growth 4.12%
As of May 31, 2020

Comparables

Edit

Attributes

Purchase Details
Open to New Investors Yes
Open to Existing Investors Yes
Minimum Initial Investment 0.00 USD
Minimum Subsequent Investment 0.00 USD
Fees
Actual 12B-1 Fee --
Actual Management Fee 0.54%
Administration Fee --
Performance Fee --
Switching Fee --
Transaction Fee --
Maximum Front Load --
Maximum Deferred Load --
Maximum Redemption Fee --
Key Dates
Inception Date 6/18/2001
Termination Date
Last Annual Report Date 2/29/2020
Last Prospectus Date 4/29/2020
Attributes
Exchange Traded Share No
Exchange Traded Note No
Enhanced Index Fund No
Fixed Distribution Fund No
High-Net Worth Individual Fund No
Index Fund No
Inverse Fund No
Leveraged Fund No
Fund of Funds No
Currency Hedged Fund No
Synthetic Replication Fund No
Has Dividend Investment Plan No
Socially Responsible Fund No
General Availability
Available for Insurance Product No
Available for Retirement Plan No
Available for RRSP No
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.